Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

AIM: The PLANET trials showed that atorvastatin 80 mg but not rosuvastatin at either 10 or 40 mg reduced urinary protein to creatinine ratio (UPCR) at similar effects on LDL‐cholesterol. However, individual changes in both UPCR and LDL‐cholesterol during treatment with these statins varied widely between patients. This inter‐individual variability could not be explained by patients’ physical or biochemical characteristics. We assessed whether the plasma concentrations of both statins were associated with LDL‐cholesterol and UPCR response. MATERIALS AND METHODS: The PLANET trials randomized patients with a UPCR of 500‐5000 mg/g and fasting LDL‐cholesterol >2.33 mmol/L to a 52‐week treatment with atorvastatin 80 mg, rosuvastatin 10 mg or 40 mg. For the current analysis, patients with available samples at week 52 and treatment compliance >80% by pill count were included (N = 295). The main outcome measurements were percentage change in UPCR and absolute change in LDL‐cholesterol (delta LDL) from baseline to week 52. RESULTS: Median (interquartile range) plasma concentration at week 52 for atorvastatin 80 mg was 3.9 ng/mL (IQR: 2.1 to 8.7), for rosuvastatin 10 mg 1.0 ng/mL (IQR: 0.7 to 2.0) and for rosuvastatin 40 mg 3.5 ng/mL (IQR: 2.0 to 6.8). Higher plasma concentration of statin was associated with larger LDL‐cholesterol reductions at week 52 [rosuvastatin r = −0.40 (P < .001); atorvastatin r = −0.28 (P = .006)]. The plasma concentration of both statins did not correlate with UPCR change [rosuvastatin r = 0.07 (P = .30); atorvastatin r = 0.16 (P = .13)]. CONCLUSIONS: Individual variation in plasma concentrations of rosuvastatin and atorvastatin was associated with LDL‐cholesterol changes in patients. The individual variation in UPCR change was not associated with the plasma concentration of both statins.